Opthalmalogical device maker SightGlass Vision said yesterday that it launched a pivotal clinical trial exploring the use of its novel lenses designed to reduce the rate of progression in children between six and nine years old.
The Palo Alto, Calif.-based company’s Cypress trial is a multicenter, double-blinded, randomized controlled clinical trial that aims to enroll 255 patients across 14 clinical sites in the U.S. and Canada. The primary endpoint of the trial is the progression of myopia over 36 months, the company said.
SightGlass Visions’s lenses are intended to reduce the progression of myopia, something the company said is not provided by current technologies on the market, which only correct for myopia.
“Although some people view myopia as an ordinary, often unavoidable condition, it has been well established that it often progresses rapidly during childhood. This results in the need for stronger prescription glasses and increases the risk of potentially blinding conditions such as glaucoma and retinal detachment in adulthood. We are pleased to be part of the Cypress program to study SightGlass’s novel lenses which could help revolutionize myopia care,” principal investgiator Katie Gilbert-Spear said in a press release.
